查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1877398

视网膜色素变性（RP）市场：依给药途径、诊断、治疗类型、疾病类型、最终用户、国家及地区划分－全球产业分析、市场规模、市场占有率及2025-2032年预测

Retinitis Pigmentosa (RP) Market, By Route of Administration, By Diagnosis, By Treatment Type, By Disease Type, By End-Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年视网膜色素变性 (RP) 市场规模价值为 147.899 亿美元，从 2025 年到 2032 年以 7.4% 的复合年增长率成长。

视网膜色素变性（RP）是一组遗传性视网膜疾病，会损伤视网膜（眼球后部的感光组织），导致进行性视力丧失。 RP患者通常会出现夜视能力下降、週边视野逐渐丧失，晚期则完全失明。 RP市场的主要驱动力是遗传性视网膜疾病诊断水平的提高、基因检测的普及以及基因治疗、干细胞治疗和光遗传学等技术的快速发展，这些技术使得更具针对性和个性化的治疗方案成为可能。然而，基因治疗的高昂成本以及Luxturna之外获批疗法的匮乏限制了市场成长。关键的市场趋势包括对基于AAV和CRISPR的治疗平台的投资增加，以及对早期基因筛检的日益重视。

视网膜色素变性（RP）市场－市场动态

医疗保健支出不断增长推动了视网膜色素变性市场的发展

预计医疗保健支出的成长将推动视网膜色素变性市场的未来成长。医疗保健支出是指在特定时期内用于医疗保健产品和服务（例如医疗、药物、住院和预防性护理）的总金额，反映了特定人群医疗保健服务的总成本。随着先进医疗技术成本的上升、人口老化以及慢性病的盛行率增加，医疗保健支出也不断增加。视网膜色素变性的医疗保健支出主要集中在改进诊断方法、开发有效疗法以及提供支持性护理以控制视力丧失。例如，根据美国国立卫生研究院（NIH）的数据，2022年美国医疗保健支出成长了4.1%，达到4.5兆美元，成长率高于2021年的3.2%。因此，不断上涨的医疗保健成本正在推动视网膜色素变性行业的成长。

视网膜色素变性（RP）市场区隔分析：

全球市场按给药途径、诊断、治疗类型、疾病类型、最终用户和地区进行细分。

在治疗类型细分市场中，基因治疗预计将在整个预测期内保持关键成长动力。视网膜色素变性的基因治疗专注于将功能基因导入患者细胞，以对抗致病突变。 Luxturna（voretigene neparvovec-rzyl）是目前唯一获得FDA批准用于治疗双等位基因RPE65突变的疗法，它能够恢復视网膜细胞中的功能性基因表现。除Luxturna外，还有多个候选药物正在临床试验中取得进展，这些药物利用AAV和其他载体技术来靶向更广泛的突变。领先生物製药公司的持续投资正在推动研发活动，并塑造该细分市场的上升趋势。例如，2025年5月，Beacon Therapeutics Holdings Limited公布了其主要候选药物laru-zova（laruparetigene zovaparvovec）治疗X连锁视网膜色素变性（XLRP）患者的II期DAWN试验的6个月中期安全性和有效性结果。

根据治疗类型划分，维生素A补充剂仍然是视网膜色素变性（RP）市场中至关重要且具有历史意义的组成部分，因为维生素A（特别是棕榈酸视黄酯）长期以来一直被研究用于延缓部分RP患者的感光细胞退化。由于目前尚无广泛核准的基因疗法（针对多种基因亚型），维生素A提供了相对简单、低技术的补充剂，可延缓视网膜功能的衰退。由于RP具有遗传异质性，维生素A等营养干预措施为患者提供了一种低成本、可扩展的选择，尤其是在缺乏先进疗法或作为辅助治疗手段的情况下。维生素A补充剂表明，即使在以先进疗法为主导的市场中，更传统的非基因疗法仍然是治疗方案的一部分。据美国国家眼科研究所（NEI）称，该研究所资助的一项试验（1984-1992年）发现，每日服用15,000国际单位（IU）的棕榈酸视黄酯可以减缓视网膜功能衰退的速度（透过视网膜电图ERG测量）。

视网膜色素变性 (RP) 市场—地理洞察

2025年，北美地区崛起成为重要的市场区域，占据超过45.2%的市占率。该地区受益于先进的医疗基础设施、大量的研发投入以及视网膜疾病发病率的上升。美国食品药物管理局（FDA）等监管机构的支持加快了创新疗法的审批，促进了市场成长。人们对遗传性疾病的日益关注以及对有效疗法的需求，是推动市场扩张的主要动力。美国为主要贡献者，其中Regeneron Pharmaceuticals和Spark Therapeutics等关键企业处于领先地位。加拿大也扮演着重要角色，专注于研发项目。生技公司与学术机构之间的合作构成了该地区竞争格局的特征，从而拓展了新型疗法的研发管线。大型製药公司的存在确保了强劲的市场环境，促进了创新和药物的可及性。

美国视网膜色素变性（RP）市场－国家概况

北美，尤其是美国和加拿大，以其许多大型企业（例如製药公司）的集中而闻名，这些企业积极致力于开发新型疗法以提供更好的治疗。例如，2024年8月，专注于发现、开发和商业化新型基因和细胞疗法及疫苗的生物技术公司Ocugen宣布，加拿大卫生部已签发“无异议函”，允许其在加拿大启动OCU400 III期临床试验。 OCU400是一种用于治疗视网膜色素变性（RP）的修饰基因疗法候选产品。这些企业专注于开发新型疗法，这将促进区域市场成长。

视网膜色素变性（RP）市场竞争格局：

视网膜色素变性市场竞争激烈，涉及众多利益相关者，包括製药公司、生物技术公司、学术机构、研究组织和医疗服务提供者。这些机构参与的活动多种多样，包括新疗法的研发、现有疗法的生产和商业化，以及为视网膜色素变性患者提供医疗服务。美国国立卫生研究院 (NIH) 和欧盟「地平线2020」计画等政府机构为视网膜色素变性的研究和开发计画提供资金和支持。这些机构在鼓励创新、促进合作以及推进眼科领域的治疗发现方面发挥着重要作用。

目录

第一章：视网膜色素变性（RP）市场概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • 视网膜色素变性（RP）市场概况（依给药途径划分）
    • 按诊断分类的视网膜色素变性（RP）市场概况
    • 视网膜色素变性 (RP) 市场概况（按治疗类型划分）
    • 视网膜色素变性 (RP) 市场概况（按疾病类型划分）
    • 视网膜色素变性（RP）市场概览（按最终用户划分）
    • 视网膜色素变性 (RP) 市场概况（按国家/地区划分）
    • 视网膜色素变性 (RP) 市场概况（按地区划分）
  • 竞争洞察

第三章：视网膜色素变性（RP）主要市场趋势

  • 视网膜色素变性（RP）市场驱动因素
    • 市场驱动因素的影响分析
  • 视网膜色素变性（RP）市场限制
    • 市场限制因素的影响分析
  • 视网膜色素变性（RP）市场机会
  • 视网膜色素变性（RP）市场未来趋势

第四章：视网膜色素变性（RP）产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：视网膜色素变性（RP）市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：视网膜色素变性（RP）市场概况

  • 2024年视网膜色素变性（RP）市占率分析
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：视网膜色素变性（RP）市场－依给药途径划分

  • 概述
    • 按给药途径分類的细分市占率分析
    • 主题
    • 口服
    • 其他的

第八章：视网膜色素变性（RP）市场－依诊断分类

  • 概述
    • 按诊断分类的细分市场份额分析
    • 视网膜电图
    • 基因检测
    • 视野检查
    • 其他的

第九章：视网膜色素变性（RP）市场－依治疗类型划分

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 视网膜植入物
    • 维生素A补充剂
    • 钙通道阻断剂
    • 二十二碳六烯酸（DHA）
    • 基因疗法
    • 其他的

第十章：视网膜色素变性（RP）市场－依疾病类型划分

  • 概述
    • 按诊断分类的细分市场份额分析
    • 体染色体显性遗传
    • X连锁视网膜色素变性
    • 体染色体隐性遗传

第十一章：视网膜色素变性（RP）市场－依终端使用者划分

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 居家照护
    • 专科诊所
    • 其他的

第十二章：视网膜色素变性（RP）市场－依地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美视网膜色素变性（RP）主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（依给药途径划分）
    • 北美市场规模及预测（依诊断分类）
    • 北美市场规模及预测（按治疗类型划分）
    • 北美市场规模及预测（依疾病类型划分）
    • 北美市场规模及预测（依最终用户划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲视网膜色素变性（RP）主要生产商
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（依给药途径划分）
    • 欧洲市场规模及预测（依诊断分类）
    • 欧洲市场规模及预测（依治疗类型划分）
    • 欧洲市场规模及预测（依疾病类型划分）
    • 欧洲市场规模及预测（依最终用户划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区视网膜色素变性（RP）主要生产商
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太地区市场规模及预测（依给药途径划分）
    • 亚太地区市场规模及预测（依诊断分类）
    • 亚太地区市场规模及预测（依治疗类型划分）
    • 亚太地区市场规模及预测（依疾病类型划分）
    • 亚太地区市场规模及预测（依最终用户划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 视网膜色素变性（RP）拉丁美洲主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（依给药途径划分）
    • 拉丁美洲市场规模及预测（依诊断分类）
    • 拉丁美洲市场规模及预测（按治疗类型划分）
    • 拉丁美洲市场规模及预测（依疾病类型划分）
    • 拉丁美洲市场规模及预测（按最终用户划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 视网膜色素变性（RP）中东和非洲主要生产商
    • 中东和非洲市场规模及预测（按国家/地区划分）
    • 中东和非洲市场规模及预测（按给药途径划分）
    • 中东及非洲市场规模及预测（依诊断分类）
    • 中东和非洲市场规模及预测（按治疗类型划分）
    • 中东和非洲市场规模及预测（按疾病类型划分）
    • 中东和非洲市场规模及预测（按最终用户划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十三章：主要供应商分析－视网膜色素变性（RP）产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Bausch Health Companies Inc.
    • Novartis AG
    • Ionis Pharmaceuticals, Inc.
    • AGTC
    • MeiraGTx Limited
    • ReNeuron Group plc
    • ProQR Therapeutics
    • Sun Pharmaceutical Industries Ltd.
    • Allergan
    • Astellas Pharma Inc.
    • AstraZeneca
    • Caladrius Biosciences, Inc.
    • Genethon
    • Gensight Biologics
    • Johnson & Johnson Private Limited
    • Orphagen Pharmaceuticals, Inc
    • Clino Corporation
    • Spark Therapeutics, Inc
    • Grupo Ferrer International, SA
    • Nanovector Srl
    • Mimetogen Pharmaceuticals Inc.
    • Others

第十四章：360度分析师视角

第十五章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5749

The Retinitis Pigmentosa (RP) Market size was valued at US$ 14,789.90 Million in 2024, expanding at a CAGR of 7.4% from 2025 to 2032.

Retinitis Pigmentosa (RP) is a group of inherited retinal disorders that cause progressive vision loss by damaging the retina, the light-sensitive tissue in the back of the eye. Individuals with RP typically have reduced night vision, gradual peripheral vision loss, and, in the advanced stages, complete blindness. The RP market is primarily driven by improved diagnosis of inherited retinal diseases, increased access to genetic testing, and rapid advances in gene therapy, stem-cell therapy, and optogenetic approaches that allow for more targeted and personalized treatment options. However, market growth is limited by the high cost of gene therapies and the scarcity of approved treatments beyond Luxturna. Key market trends include increased investment in AAV- and CRISPR-based therapeutic platforms, as well as a greater emphasis on early genetic screening.

Retinitis Pigmentosa (RP) Market- Market Dynamics

Rising Healthcare Expenditure Drives Growth In The Retinitis Pigmentosa Market

The increase in healthcare expenditure is expected to drive future growth in the retinitis pigmentosa market. Healthcare expenditure is the total amount of money spent on healthcare goods and services, such as medical treatments, medications, hospitalizations, and preventive care, over a given time period, indicating the overall cost of healthcare provision within a population. Healthcare spending is increasing as the cost of advanced medical technologies rises, populations age, and chronic diseases become more prevalent. Healthcare spending for retinitis pigmentosa is concentrated on improving diagnostic methods, developing effective treatments, and providing supportive care to manage vision loss. For example, according to the National Institutes of Health, a US-based government agency, healthcare spending in the United States increased by 4.1% in 2022 to $4.5 trillion, representing a faster growth rate than the 3.2% increase observed in 2021. As a result, rising healthcare costs are fueling the growth of the retinitis pigmentosa industry.

Retinitis Pigmentosa (RP) Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Route of Administration, Diagnosis, Treatment Type, Disease Type, End-Users, and Region.

In treatment type segment, the gene therapy category is expected to remain a key growth driver throughout the forecast period. Gene therapy for retinitis pigmentosa focuses on delivering functional genes to patient cells to combat disease-causing mutations. Luxturna (voretigene neparvovec-rzyl) is the only FDA-approved therapy for biallelic RPE65 mutations, which restores functional gene expression in retinal cells. Beyond Luxturna, several candidates are making progress in clinical trials, utilizing AAV and other vector technologies to target a broader range of mutations. Continued investment from leading biopharmaceutical companies is boosting development activity and shaping the segment's upward trajectory. For instance, in May 2025, Beacon Therapeutics Holdings Limited reported 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company's lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP).

Based on Treatment Type segment, Vitamin A supplements remain an essential and historically significant segment of the RP market because vitamin A (specifically, retinol palmitate) has long been studied for its ability to slow photoreceptor degeneration in some RP patients. In the absence of broadly approved gene therapies (for many genetic subtypes), vitamin A has provided a relatively simple, low-tech supplement that may delay the decline in retinal function. Because RP is genetically heterogeneous, nutritional interventions such as vitamin A provide patients with a low-cost, scalable option, especially in settings where advanced therapies are unavailable or as a complementary measure. Vitamin A supplementation exemplifies how more traditional, non-gene-based treatments remain part of the therapeutic mix, even in a market dominated by sophisticated therapies. According to the NEI, a trial supported by the institute (1984-1992) discovered that taking 15,000 IU of vitamin A palmitate daily could slow the rate of functional retinal decline (measured using ERG).

Retinitis Pigmentosa (RP) Market- Geographical Insights

In 2025, North America emerged as a significant region, accounting for more than 45.2% of the market. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a rising incidence of retinal disease. Regulatory support from agencies such as the FDA expedites the approval of innovative therapies, resulting in market growth. The growing awareness of genetic disorders, as well as the demand for effective treatments, are driving this expansion. The United States is the primary contributor, with key players including Regeneron Pharmaceuticals and Spark Therapeutics leading the way. Canada also plays an important role, focusing on R&D initiatives. Collaborations between biotech firms and academic institutions characterize the competitive landscape, thereby expanding the pipeline of novel therapies. The presence of major pharmaceutical companies ensures a strong market environment that promotes innovation and accessibility.

United States Retinitis Pigmentosa (RP) Market- Country Insights

North America, particularly the United States, Canada is known for its large concentration of major players such as pharmaceutical companies, which actively pursue the development of novel therapies for better treatment. For instance, in August 2024, Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Health Canada has issued a "No Objection Letter" to begin the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy product candidate for retinitis pigmentosa (RP). These are focused on the development of novel therapeutics, which will boost regional market growth.

Retinitis Pigmentosa (RP) Market- Competitive Landscape:

The Retinitis Pigmentosa market is competitive, with a diverse range of stakeholders including pharmaceutical companies, biotechnology firms, academic institutions, research organizations, and healthcare providers. These organizations are involved in a variety of activities, including research and development of new therapies, manufacturing and commercialization of existing treatments, and providing healthcare services to retinitis pigmentosa patients. Government agencies, including the National Institutes of Health (NIH) in the United States and the European Commission's Horizon 2020 program, fund and support retinitis pigmentosa research and development initiatives. These organizations play an important role in encouraging innovation, facilitating collaborations, and advancing therapeutic discoveries in the field of ophthalmology.

Recent Developments:

In December 2024, Bausch + Lomb, a subsidiary of Bausch Health, has acquired Elios Vision Inc., the developer of the ELIOS system, a minimally invasive glaucoma surgery (MIGS) procedure that uses an excimer laser. This acquisition demonstrates Bausch + Lomb's commitment to providing advanced glaucoma treatment solutions, thereby improving patient care around the world.

In May, 2024, The EYE-RD Global Registry was introduced by Johnson & Johnson at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). This non-interventional global registry is the first of its kind and aims to collect longitudinal clinical data on patients with inherited retinal diseases (IRDs), such as X-linked retinitis pigmentosa. The registry's goal is to fill knowledge gaps by providing real-world insights into disease progression and patient experiences, which will aid in IRD research, diagnosis, and treatment strategies.

In August 2025, Novartis (CH) has announced a strategic collaboration with a leading biotechnology company to co-develop a novel gene therapy to treat Retinitis Pigmentosa. This collaboration is expected to leverage both companies' genetic research expertise, potentially shortening the development timeline and expanding the therapeutic options available to patients. Such collaborations not only strengthen Novartis' research capabilities, but also reflect an industry-wide trend toward collaborative innovation.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Bausch Health Companies Inc.
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • AGTC
  • MeiraGTx Limited
  • ReNeuron Group plc
  • ProQR Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Astellas Pharma Inc.
  • AstraZeneca
  • Caladrius Biosciences, Inc.
  • Genethon
  • Gensight Biologics
  • Johnson & Johnson Private Limited
  • Orphagen Pharmaceuticals, Inc
  • Clino Corporation
  • Spark Therapeutics, Inc
  • Grupo Ferrer International, S.A.
  • Nanovector S.r.l
  • Mimetogen Pharmaceuticals Inc.
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Topical
  • Oral
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2019 - 2032

  • Electroretinogram
  • Genetic Testing
  • Visual Field Testing
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Retinal Implants
  • Vitamin A Supplements
  • Calcium channel blockers
  • Docosahexaenoic acid (DHA)
  • Gene Therapy
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Autosomal Dominant
  • X-linked RP
  • Autosomal Recessive

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Retinitis Pigmentosa (RP) Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Retinitis Pigmentosa (RP) Market Snippet by Route of Administration
    • 2.1.2. Retinitis Pigmentosa (RP) Market Snippet by Diagnosis
    • 2.1.3. Retinitis Pigmentosa (RP) Market Snippet by Treatment Type
    • 2.1.4. Retinitis Pigmentosa (RP) Market Snippet by Disease Type
    • 2.1.5. Retinitis Pigmentosa (RP) Market Snippet by End-Users
    • 2.1.6. Retinitis Pigmentosa (RP) Market Snippet by Country
    • 2.1.7. Retinitis Pigmentosa (RP) Market Snippet by Region
  • 2.2. Competitive Insights

3. Retinitis Pigmentosa (RP) Key Market Trends

  • 3.1. Retinitis Pigmentosa (RP) Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Retinitis Pigmentosa (RP) Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Retinitis Pigmentosa (RP) Market Opportunities
  • 3.4. Retinitis Pigmentosa (RP) Market Future Trends

4. Retinitis Pigmentosa (RP) Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Retinitis Pigmentosa (RP) Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Retinitis Pigmentosa (RP) Market Landscape

  • 6.1. Retinitis Pigmentosa (RP) Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Retinitis Pigmentosa (RP) Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 7.1.2. Topical
    • 7.1.3. Oral
    • 7.1.4. Others

8. Retinitis Pigmentosa (RP) Market - By Diagnosis

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
    • 8.1.2. Electroretinogram
    • 8.1.3. Genetic Testing
    • 8.1.4. Visual Field Testing
    • 8.1.5. Others

9. Retinitis Pigmentosa (RP) Market - By Treatment Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 9.1.2. Retinal Implants
    • 9.1.3. Vitamin A Supplements
    • 9.1.4. Calcium channel blockers
    • 9.1.5. Docosahexaenoic acid (DHA)
    • 9.1.6. Gene Therapy
    • 9.1.7. Others

10. Retinitis Pigmentosa (RP) Market - By Disease Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
    • 10.1.2. Autosomal Dominant
    • 10.1.3. X-linked RP
    • 10.1.4. Autosomal Recessive

11. Retinitis Pigmentosa (RP) Market - By End-Users

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Homecare
    • 11.1.4. Specialty Clinics
    • 11.1.5. Others

12. Retinitis Pigmentosa (RP) Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Retinitis Pigmentosa (RP) Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Retinitis Pigmentosa (RP) Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Retinitis Pigmentosa (RP) Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Retinitis Pigmentosa (RP) Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Retinitis Pigmentosa (RP) Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Retinitis Pigmentosa (RP) Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Bausch Health Companies Inc.
    • 13.2.2. Novartis AG
    • 13.2.3. Ionis Pharmaceuticals, Inc.
    • 13.2.4. AGTC
    • 13.2.5. MeiraGTx Limited
    • 13.2.6. ReNeuron Group plc
    • 13.2.7. ProQR Therapeutics
    • 13.2.8. Sun Pharmaceutical Industries Ltd.
    • 13.2.9. Allergan
    • 13.2.10. Astellas Pharma Inc.
    • 13.2.11. AstraZeneca
    • 13.2.12. Caladrius Biosciences, Inc.
    • 13.2.13. Genethon
    • 13.2.14. Gensight Biologics
    • 13.2.15. Johnson & Johnson Private Limited
    • 13.2.16. Orphagen Pharmaceuticals, Inc
    • 13.2.17. Clino Corporation
    • 13.2.18. Spark Therapeutics, Inc
    • 13.2.19. Grupo Ferrer International, S.A.
    • 13.2.20. Nanovector S.r.l
    • 13.2.21. Mimetogen Pharmaceuticals Inc.
    • 13.2.22. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us